Read this topic

Zolpidem, zopiclone and zaleplon, collectively called the 'Z-drugs', are prescribed constantly for short-term insomnia (difficulty sleeping), often on the mistaken assumption that because they are chemically distinct from benzodiazepines, they are somehow safer or non-addictive. That assumption matters clinically because it changes prescribing behaviour: patients and even some prescribers treat Z-drugs as low-risk repeat prescriptions, when in fact they carry very similar dependence, tolerance and falls risks to benzodiazepines. Understanding exactly where Z-drugs are similar to, and different from, benzodiazepines is the whole point of this concept.

GABA (gamma-aminobutyric acid) is the brain's main inhibitory, or calming, neurotransmitter (a chemical messenger between nerve cells). The GABA-A receptor is a chloride channel (a pore in the nerve cell membrane that lets negatively charged chloride ions in) that GABA opens; more chloride entering makes the nerve cell less likely to fire, producing calm or sedation. The receptor has several different binding sites, GABA itself binds one, and a separate 'benzodiazepine site' can be bound by other molecules that do not activate the channel alone, but make it respond MORE strongly when GABA is present, an effect called POSITIVE ALLOSTERIC MODULATION (boosting a receptor's response from a site other than its main one).

Both benzodiazepines and Z-drugs bind this same benzodiazepine site on the GABA-A receptor and work as positive allosteric modulators, which is why their effects and their risks overlap so heavily. The key pharmacological difference is RECEPTOR SUBTYPE SELECTIVITY: the GABA-A receptor comes in several subtypes built from different combinations of protein subunits, and zolpidem in particular is relatively selective for the alpha-1 subtype, which is thought to mediate sedation and hypnosis (drug-induced sleep) more than anxiolysis (anxiety reduction). Benzodiazepines bind subtypes more broadly, which is why they produce a wider spread of effects: anxiolytic, hypnotic, muscle-relaxant and anticonvulsant (seizure-preventing) all at once, whereas Z-drugs lean toward the hypnotic effect specifically.

A distinctive, FDA/MHRA-flagged warning for Z-drugs, especially zolpidem, is complex sleep behaviours: sleepwalking, sleep-eating, or even sleep-driving, performed while still partly or fully asleep, with no memory of the episode afterwards. This risk rises sharply when Z-drugs are combined with alcohol or other sedatives, e.g. a patient on zolpidem who also drinks most evenings is at materially higher risk of one of these episodes than a patient taking zolpidem alone. Equally important: dependence, tolerance and rebound insomnia (worse sleep than baseline after stopping) all occur with Z-drugs much as they do with benzodiazepines, so the 'not a benzodiazepine, so it's not addictive' reassurance patients often repeat is only partly true and should be corrected.

Consider a patient prescribed zopiclone for two weeks of acute insomnia after a bereavement. Used short-term and then stopped, this is reasonable practice: they get symptomatic relief without meaningfully building tolerance or dependence. Now consider a second patient who has taken zolpidem nightly for eight months because 'it's not addictive'. Stopping abruptly risks rebound insomnia and, potentially, a withdrawal syndrome similar to benzodiazepine withdrawal, so their dose needs a gradual taper, the same principle used for long-term benzodiazepine discontinuation, not an abrupt stop.

Barbiturates also act at the GABA-A receptor but via a different mechanism: at high doses barbiturates increase the DURATION the channel stays open (and can even open it without GABA present at all), which is why barbiturate overdose is far more dangerous, causing severe respiratory depression, than benzodiazepine or Z-drug overdose, which mainly increases the FREQUENCY of channel opening and needs GABA present to have any effect. Primary insomnia disorder without an underlying cause looks similar to secondary insomnia (insomnia caused by depression, anxiety, pain or another condition) on the surface, but management differs: secondary insomnia needs the underlying condition treated first, not just a hypnotic.

Insomnia itself is a clinical diagnosis based on history: difficulty falling or staying asleep, at least three nights a week, causing daytime impairment. Before prescribing a Z-drug, a clinician should screen for alcohol and other sedative use, since this potentiates every risk on this list, and check whether the insomnia is primary or secondary to another treatable condition. There is no blood test for Z-drug toxicity in routine practice; overdose is assessed clinically by conscious level and respiratory rate.

NICE guidance and the British National Formulary (BNF) both recommend Z-drugs and benzodiazepine hypnotics for short-term use only, typically no more than two to four weeks, with the lowest effective dose and non-drug measures (sleep hygiene, cognitive behavioural therapy for insomnia) as first-line where possible. Flumazenil, a benzodiazepine-site antagonist (a drug that blocks the site without activating it), reverses both benzodiazepine and Z-drug overdose because it competes for the same binding site; it is not used for barbiturate overdose, which needs supportive care instead. Long-term Z-drug users being stopped should have a gradual dose taper, following the same principle as benzodiazepine discontinuation described in the Maudsley Prescribing Guidelines in Psychiatry.

If a vignette describes a patient with no memory of an overnight episode, e.g. eating or wandering while asleep, on a Z-drug, think complex sleep behaviour, and if it asks what reverses a Z-drug overdose, the answer is flumazenil, because it shares the benzodiazepine binding site.

Z-drugs act at the same benzodiazepine site on the GABA-A receptor as benzodiazepines, so despite being chemically distinct, they carry the same dependence, falls and complex-sleep-behaviour risks, and should be prescribed short-term only.